Modular Medical shares jump 20.71% intraday after validating Pivot controller line for human-use production ahead of Q1 2026 launch.

Modular Medical surged 20.71% intraday following the announcement of successful validation of its Pivot controller line, a critical step toward its Q1 2026 commercial launch of the tubeless, removable 3-milliliter patch pump. The validation confirms manufacturing readiness for high-volume production, addressing a $3 billion market for adult "almost-pumpers" with an affordable, user-friendly design. The company emphasized this milestone reduces commercialization risks, strengthens its competitive position in the insulin pump market, and aligns with its goal to capture significant market share. CEO Jeb Besser highlighted the scalable production capability as a key differentiator, reinforcing investor confidence in the product’s potential to meet unmet demand. Despite noting that the Pivot remains uncleared by the FDA, the news underscored progress in execution and operational readiness, directly correlating with the intraday price surge.